34 results about "Insulin used" patented technology

Method and system for providing basal profile modification in insulin therapy for use with infusion devices includes periodically monitoring the analyte levels of a patient for a predetermined period of time in order to determine, based on the monitored analyte levels, an appropriate modification factor to be incorporated into the underlying basal profile which was running at the time the periodic monitoring of the analyte levels were performed.

An insulin pump for use in conjunction with a mobile communication terminal capable of measuring a blood glucose level, and a network for transmitting control information for the insulin pump are disclosed. The insulin pump includes an external input port, an output port, memory, a key input unit, a control unit, and a motor driver. The external input port receives information on the amounts of insulin to be injected. The output port outputs information on the amounts of insulin injected. The memory stores the information on the amounts of insulin injected. The key input unit inputs the status of a user. The control unit extracts the information on the amounts of insulin to be injected from the memory. The motor drive operates a soft motor to supply insulin.

Described and illustrated is a system for management of diabetes that includes an infusion pump, glucose sensor and controller with a method programmed in the controller. The infusion pump is configured to deliver insulin. The glucose sensor senses glucose levels in the subject and provide output signals representative of the glucose levels in the subject. The controller is programmed receives signals from at least one of the glucose sensor and the pump and configured to issue signals to the pump to deliver an amount of insulin determined by a feedback controller that utilizes a model predictive control based on desired glucose levels, insulin amount delivered and measured glucose levels of the subject. The controller is also configured to deliver insulin using a tuning factor (R) for a model predictive controller in the microcontroller as a conservative setting otherwise the system maintains a current tuning factor (R) for the controller.

A closed loop system or semi-closed loop system for infusing insulin using sensor values applies a redundant sensor system as a fail-safe method against sensor failure. The redundant glucose sensors are used corroborate each other and a failing sensor is detected if the sensors no longer corroborate each other. The use of redundant sensors has the additional benefit of producing better sensor signals compared to the use of a single sensor.

Described and illustrated is a system for management of diabetes that includes an infusion pump, glucose sensor and controller with a method programmed into the controller. The infusion pump is configured to deliver insulin to a subject. The glucose sensor is configured to sense glucose levels in the subject and provide output signals representative of the glucose levels in the subject. The controller is programmed receives signals from at least one of the glucose sensor and the pump and configured to issue signals to the pump to deliver an amount of insulin determined by a feedback controller that utilizes a model predictive control of the subject based on desired glucose levels, insulin amount delivered and measured glucose levels of the subject. The controller is also configured to deliver insulin using a tuning factor based on either one of an omission index module or a calibration index module.

An insulin infusion set (30) for use with an inserter (40) is disclosed. The infusion set (30) includes an extension set (50). The extension set (50) includes a housing (70), a base (90) and a latching device (82). The base (90) houses a base septum (120) and an infusion cannula (42). The latching device (82) releasably attaches the housing (70) to the base. When the housing (70) is attached to the base (90), a part of the housing (70) extends into and opens the base septum (120).

A pharmaceutical formulation for absorption through oral mucosae comprising an effective amount of (a) a pharmaceutical agent in mixed micellar form, (b) at least one micelle-forming compound selected from the group comprising an alkali metal alkyl sulfate and a polyoxyethylene sorbitan monooleate, (c) a block copolymer of polyoxyethylene and polyoxypropylene, (d) at least one additional micelle-forming compound, and (e) a suitable solvent. The invention also provides a metered dose dispenser (aerosol or non-aerosol) containing the present formulation and a method of administering insulin using the metered dose dispenser comprising administering split doses of a formulation containing insulin before and after each meal.

Described and illustrated is a system for management of diabetes that includes an infusion pump, glucose sensor and controller with a method programmed in the controller. The infusion pump is configured to deliver insulin. The glucose sensor senses glucose levels in the subject and provide output signals representative of the glucose levels in the subject. The controller is programmed receives signals from at least one of the glucose sensor and the pump and configured to issue signals to the pump to deliver an amount of insulin determined by a feedback controller that utilizes a model predictive control based on desired glucose levels, insulin amount delivered and measured glucose levels of the subject. The controller is also configured to deliver insulin using a tuning factor (R) for a model predictive controller in the microcontroller as a conservative setting otherwise the system maintains a current tuning factor (R) for the controller.

An insulin pump for use in conjunction with a mobile communication terminal capable of measuring a blood glucose level, and a network for transmitting control information for the insulin pump are disclosed. The insulin pump includes an external input port, an output port, memory, a key input unit, a control unit, and a motor driver. The external input port receives information on the amounts of insulin to be injected. The output port outputs information on the amounts of insulin injected. The memory stores the information on the amounts of insulin injected. The key input unit inputs the status of a user. The control unit extracts the information on the amounts of insulin to be injected from the memory. The motor drive operates a soft motor to supply insulin.

The invention discloses an insulin-used syringe needle with an adjustable injecting depth. The insulin-used syringe needle comprises a needle seat, a steel needle is connected in the needle seat through a bonding agent, internal threads for connecting the external threads on the front end of an insulin pen are arranged in the needle seat, a limit ring is sleeved on the needle seat, the external threads are arranged on the outer surface of the needle seat, the internal threads are arranged in the limit ring, and the needle seat and the limit ring is connected via engagement of the outer threads. The insulin-used syringe needle has the main beneficial effects that the risk of injecting into a muscle layer by mistake due to over-deep needle insertion is effectively prevented, a patient can adjust the injecting depth according to the self situation of fatness and thinness, so as to select the injecting depth suitable for self, and the practicability is strong.

The present invention provides an insulin-specific assay and an assay reagent capable of sensitively and specifically assaying insulin using an antibody having a property of reacting with insulin bound to an anti-insulin antibody while not reacting with insulin not bound to an anti-insulin antibody, without being affected by proinsulin and insulin analogs.

An insulin pump data acquisition device & system including: an insulin pump data acquisition device for use with an insulin pump, the data acquisition device including a holster having a wall defining an interior volume and an exterior volume, the exterior volume being sized to removably secure the insulin pump; an environmental sensor operable to generate environmental data in response to environmental conditions; memory operably connected to the environmental sensor, the memory being operable to store the environmental data; a controller operably connected to the environmental sensor and the memory, the controller being operable to control reading of the environmental data from the environmental sensor and writing of the environmental data to the memory; and a battery operably connected to power the environmental sensor, the memory, and the controller. The environmental sensor, the memory, the controller, and the battery are disposed within the interior volume.

The present invention refers to a method for producing a human insulin analogue with high efficiency and excellent yield, by means of a biotechnological process comprising transformation of a Pichia pastoris yeast strain. In particular, the invention refers to a biotechnological process for obtaining aspart insulin.

The invention relates to an infusion pipeline for an insulin pump, and belongs to products in the medical field. The infusion pipeline is an insulin infusion pipeline which is provided with a universal Luer taper and cooperates with the insulin pump for use. The infusion pipeline serves as a consumable material of the insulin pump and comprises a needle aid, a needle aid protection sleeve, a sticking needle base, a hose needle, a sticking needle base protection cap, a pipe needle base joint and a pipeline body; the needle aid can be accurately and quickly inserted into a human body with littlepain, double spring design is adopted, one spring is responsible for pushing out the needle, and the other spring is responsible for pulling out and retrieving a steel needle; the needle aid is provided with the protection sleeve, and pressing by accident is prevented; the sticking needle base has the effects of assisting pulling and needle tubing fall off detection and is in rapid sealing connection with the pipe needle base joint; the hose needle is fixed to the position of a four-handle grip of the sticking needle base, and sealing is conducted through silica gel; the direction of the pipeneedle base joint can be adjusted freely to avoid pipeline confusion and knotting; the pipeline adopts the universal Luer taper, and the adaptability is high. The sticking needle base, the needle aid, the pipeline needle base joint and the sticking needle base protection cap are all assembled through pressing clamping locks.

The present invention relates to human insulin expression plasmids and a method for producing insulin using the same. The plasmids comprise a sequence encoding a compound of the formula R—B—X-A, in which R is a leader peptide of the formula of Met-Thr-Met-Ile-Thr-Y (SEQ ID NO: 36), in which Y is one selected from lysine, arginine, a peptide containing lysine as an amino acid at its C-terminal, or a peptide containing arginine as an amino acid at its C-terminal; B is human insulin B-chain or analogue thereof; X is a peptide connecting B with A; and A is human insulin A-chain or analogue thereof. The method for preparing insulin using the plasmids according to the present invention converts the proinsulin fusion protein into human insulin in a single enzymatic cleavage process and minimizes the generation of by-products after the enzymatic cleavage, thereby producing insulin at a high yield. Therefore, the plasmids according to the present invention and the method for preparing insulin using the same can be usefully applied to the industrial mass-production of human insulin.

The invention discloses ginsenoside-insulin nano gel as well as a preparation method and application thereof. A hypoglycemic drug insulin used as a drug effect ingredient is combined with ginsenosidegel nano-particles having an effect of reducing blood sugar, so that the ginsenoside-insulin nano gel having double blood sugar reduction effects is prepared. By using the ginsenoside gel nano-particles, slow-release transdermal drug administration of insulin can be realized, and a side effect caused by injecting the insulin is avoided. The ginsenoside-insulin nano gel disclosed by the invention is used for preparing a transdermal drug administration preparation and has the characteristics of quick transdermal absorption rate, security, stability, no pain, convenience and the like; moreover, the preparation method has the advantages of simpleness, low production cost, and easiness for amplification.

The present invention relates to an insulin analog that has reduced insulin receptor binding affinity for the purpose of increasing the blood half-life of insulin, and long-acting insulin, a conjugate, and a method of preparing long-acting insulin using the same.

The present invention provides an insulin-specific assay and an assay reagent capable of sensitively and specifically assaying insulin using an antibody having a property of reacting with insulin bound to an anti-insulin antibody while not reacting with insulin not bound to an anti-insulin antibody, without being affected by proinsulin and insulin analogs.

The invention discloses an application of a traditional Chinese medicine composition in the preparation of medicines for preparing diabetic ketoacidosis complicated with leukemoid reaction. The traditional Chinese medicine composition comprises herbal medicines such as ginseng, rhizoma polygonati, rhizoma atractylodis, radix sophorae flavescentis, poria cocos, dwarf lilyturf tuber, prepared fleeceflower root, rehmannia root, dogwood, coptidis rhizoma and fortune eupatorium herb. The traditional Chinese medicine composition is mainly used for tonifying qi and yin, strengthening spleen and transferring body fluid, and has the effects of clearing away heat, eliminating dampness and promoting blood circulation to remove meridian obstruction. After the traditional Chinese medicine composition is taken, the dosage of insulin used by patients is gradually reduced, the blood glucose control is normal and stable, the time of urine acetone bodies turning to negative is obviously shortened, and the state of illness can be controlled as soon as possible.

The present application discloses the preparation of peptides, including insulin and insulin derivatives, using efficient methods for solid-phase and solution phase peptide synthesis.

The invention discloses a preparation method of polypeptide-insulin nanoparticle. In the invention, insulin monomer is dissolved in a solution, and a certain proportion of polypeptide having the function of inhibiting insulin fibrosis is added at the same time; and then the above solution is stirred for a period of time under certain conditions. , so that the polypeptide and insulin are fully reacted to obtain pentapeptide-insulin supramolecular nanoparticles. The operation of the invention is simple, and the obtained supramolecular nanoparticles do not produce burst release, and have good sustained release effect, and the polypeptide can inhibit the fibrosis of insulin. This product has the potential to solve the dangers of hypoglycemia caused by the sudden release of insulin itself during clinical use and the problems of fibrosis during insulin use, and has broad application prospects in the treatment of type I diabetes and type II diabetes.

The present application discloses the preparation of peptides, including insulin and insulin derivatives, using efficient methods for solid-phase and solution phase peptide synthesis.

The invention relates to the field of biotechnology and medicine, and specifically to insulin-containing preparations used, in particular, for treating diabetes mellitus. The present preparation comprises a mixture of insulin and a pharmacologically acceptable polymer having a hydrodynamic diameter of more than 4.5+ / -0.5 nanometers. As said polymer, at least one polymer having a molecular weight of 20-70 kDa may optimally be used, selected from a group including: dextran, polyethylene glycol and albumin. As regards insulin preparations used in the composition of the preparation, it is possible to use human recombinant insulin and genetically engineered analogues thereof used in the form of commercial preparations. Experiments have shown that using the aforementioned polymers provides insulin preparations with a prolonged effect without the use of chemical or genetic engineering methods to modify insulin molecules. The method is not specific and can thus be applied across a wide range of therapeutic proteins.

The invention discloses a method for directly secreting and expressing mature double-chain insulin glargine using Saccharomyces cerevisiae. This method first constructs chassis cells that overexpress Kex2, and then transfers the tandem signal peptide and codon-optimized insulin glargine DNA into the chassis cells that overexpress Kex2 to form a Saccharomyces cerevisiae co-expression system, and performs protein expression and purification to obtain Insulin glargine. This method greatly reduces the difficulty of the insulin glargine production process, simplifies the tedious and complex multi-step downstream processing of the traditional process, and allows yeast cells to directly complete the modification work within the cell. At the same time, this method reduces the complexity of purification and can directly extract mature insulin protein from the culture medium through one-step, relatively low-cost ion exchange purification. In addition, by avoiding the use of ingredients such as trypsin, nearly 50% of the by-products in the original process are avoided, which improves the fermentation efficiency of carbon sources and other nutrients in the culture medium, and has good prospects for promotion and application.

The invention relates to the field of insulin injection pumps, in particular to an insulin pump suitable for all-weather use.The insulin pump suitable for all-weather use comprises a medicine storage device and a control system, a semiconductor refrigeration device and a temperature sensor are arranged in the medicine storage device, the temperature sensor outputs temperature data in the medicine storage device to the control system, and the control system outputs a work instruction to the semiconductor refrigeration device.Through coordination of the semiconductor refrigeration device and the temperature sensor, the insulin pump suitable for all-weather use solves the problem that a diabetic patient uses an insulin pump to inject insulin at high temperature and is suitable for use in summer and hot regions.In terms of characteristics of the semiconductor refrigeration device, the size and the weight of the insulin pump cannot be increased obviously, and the insulin pump cannot produce noise during use and cannot bring inconvenience to users.

The invention discloses an insulin pen suitable for visually impaired patients, which comprises a pen cover, an adjustment cylinder arranged inside the pen cover, a piston body arranged inside the adjustment cylinder, a piston rod fixedly connected with the piston body, and a piston rod installed at the bottom of the adjustment cylinder. The push cylinder at the end, the pen cover is composed of a support sleeve and a connecting shell, and the connecting shell is fixedly connected with the supporting sleeve, and the connecting shell is provided with a dosage elastic reminder device for visually impaired patients to use insulin pens in public places, which is suitable for The insulin pen used by visually impaired patients is provided with a pen cover, and the pen cover is composed of a support sleeve for accommodating the adjustment cylinder and the push cylinder, and a connection shell connecting the support sleeve, and the dose elastic reminder device is provided on the connection shell, Therefore, when the visually impaired patients use it in public places, it can play the role of real-time silent reminder of the dose used by the patient, thereby facilitating the use of the patient.

An insulin infusion set (30) for use with an inserter (40) is disclosed. The infusion set (30) includes an extension set (50). The extension set (50) includes a housing (70), a base (90) and a latching device (82). The base (90) houses a base septum (120) and an infusion cannula (42). The latching device (82) releasably attaches the housing (70) to the base. When the housing (70) is attached to the base (90), a part of the housing (70) extends into and opens the base septum (120).